Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Background. Interstitial lung disease (ILD) is the most common complication of systemic
sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta‐analysis was to …

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

Objectives Randomized controlled trials have shown that cyclophosphamide (CYC) was an
option in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The observed …

Background and objective Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …

The efficacy and safety of mycophenolate mofetil (MMF) has been studied in patients with
systemic sclerosis (SSc)-related interstitial lung disease (ILD) with moderate–severe …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

Objective This study systematically compares the efficacy and adverse events of
mycophenolate mofetil (MMF) and cyclophosphamide (CYC) in patients with systemic …

Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …